Concepedia

Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis

Anthony C. Wood, Ariel Perez Perez, Brian Arciola, Kedar Patel, Grace Johnson, Elizabeth DiMaggio, Christina A. Bachmeier, Kayla Reid, Salvatore Carallo, Melanie Hidalgo Vargas,

Transplantation and Cellular Therapy · 2022 · 31 citations · 21 references

DOIFull text

Open access

Concepts

References

21

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett et al. · New England Journal of Medicine · 2017 · 5.9K citations · Full text

, , +16

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Stephen J. Schuster, Michael Bishop, Constantine S. Tam et al. · New England Journal of Medicine · 2018 · 4K citations · Full text

, , +15

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

Mohamed L. Sorror, Michael B. Maris, Rainer Storb et al. · Blood · 2005 · 2.9K citations · Full text

, , +11

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

M. Lia Palomba, Leo I. Gordon, Matthew A. Lunning et al. · The Lancet · 2020 · 2.3K citations

, , +13

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

Frederick L. Locke, David B. Miklos, Caron A. Jacobson et al. · New England Journal of Medicine · 2021 · 1.5K citations · Full text

, , +8